Figure 1From: IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjectsIL-33 is reduced in non-lean subjects. The concentration of serum IL-33 was measured in lean (nā=ā10) and non-lean (nā=ā21, 8 overweight and 13 obese) non-diabetic subjects. (a) Non-lean subjects had significantly (Pā=ā0.01, non-parametric Mann-Whitney test) lower concentrations of IL-33 compared to lean controls. The graph shows the median of the 'minimum to maximum' IL-33 values. (b) Overweight subjects had significantly (Pā=ā0.003, non-parametric Mann-Whitney test; the overall non-parametric Kruskal-Wallis test was Pā=ā0.01) lower concentrations of IL-33 compared to lean controls. The graph shows the median of the āminimum to maximumā IL-33 values. (c) IL-33 is negatively correlated with the BMI in non-diabetic subjects, which was confirmed in lean/overweight (nā=ā18; Spearman rā=ā-0.76, Pā=ā0.0003) but not obese (nā=ā13; body weight: Spearman rā=ā-0.115, Pā=ā0.7; BMI: Spearman rā=ā0.08, Pā=ā0.8) subjects. (d) IL-33 is negatively correlated with the body weight (nā=ā31; Spearman rā=ā-0.38, Pā=ā0.034) in non-diabetic subjects, which was confirmed in lean/overweight (nā=ā18; Spearman rā=ā-0.57, Pā=ā0.013) but not obese (nā=ā13) subjects.Back to article page